Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma
© 2018 Wiley Periodicals, Inc..
Positron emission tomography-computed tomography (PET-CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET-CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET-CT abnormalities. Patients (N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions. The median maximum standardized uptake value (SUVmax ) for the entire cohort was 5.9 (range 1.5-48.3). Presence of at least 3 FLs and EMD predicted inferior overall survival (OS); median OS was 57.8 months for patients with 3 or more FLs and 103.6 months for patients with fewer than 3 FLs (P = .003). The median OS was 45.5 and 71.8 months for patients with and without EMD, respectively (P = .004). No clear SUVmax cutoff was predictive of progression-free survival or OS. PET-CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with novel agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
American journal of hematology - 93(2018), 12 vom: 15. Dez., Seite 1518-1523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aljama, Mohammed A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 19.08.2019 Date Revised 19.08.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ajh.25279 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288321405 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288321405 | ||
| 003 | DE-627 | ||
| 005 | 20231225060021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.25279 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0961.xml |
| 035 | |a (DE-627)NLM288321405 | ||
| 035 | |a (NLM)30194770 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aljama, Mohammed A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2019 | ||
| 500 | |a Date Revised 19.08.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 Wiley Periodicals, Inc. | ||
| 520 | |a Positron emission tomography-computed tomography (PET-CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET-CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET-CT abnormalities. Patients (N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions. The median maximum standardized uptake value (SUVmax ) for the entire cohort was 5.9 (range 1.5-48.3). Presence of at least 3 FLs and EMD predicted inferior overall survival (OS); median OS was 57.8 months for patients with 3 or more FLs and 103.6 months for patients with fewer than 3 FLs (P = .003). The median OS was 45.5 and 71.8 months for patients with and without EMD, respectively (P = .004). No clear SUVmax cutoff was predictive of progression-free survival or OS. PET-CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with novel agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a advanced imaging | |
| 650 | 4 | |a myeloma | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 700 | 1 | |a Sidiqi, M Hasib |e verfasserin |4 aut | |
| 700 | 1 | |a Buadi, Francis K |e verfasserin |4 aut | |
| 700 | 1 | |a Lacy, Martha Q |e verfasserin |4 aut | |
| 700 | 1 | |a Gertz, Morie A |e verfasserin |4 aut | |
| 700 | 1 | |a Dispenzieri, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Dingli, David |e verfasserin |4 aut | |
| 700 | 1 | |a Muchtar, Eli |e verfasserin |4 aut | |
| 700 | 1 | |a Fonder, Amie L |e verfasserin |4 aut | |
| 700 | 1 | |a Hayman, Suzanne R |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbs, Miriam A |e verfasserin |4 aut | |
| 700 | 1 | |a Gonsalves, Wilson I |e verfasserin |4 aut | |
| 700 | 1 | |a Warsame, Rahma M |e verfasserin |4 aut | |
| 700 | 1 | |a Kourelis, Taxiarchis |e verfasserin |4 aut | |
| 700 | 1 | |a Hwa, Yi Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Kyle, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Go, Ronald S |e verfasserin |4 aut | |
| 700 | 1 | |a Rajkumar, S Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Shaji K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 93(2018), 12 vom: 15. Dez., Seite 1518-1523 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2018 |g number:12 |g day:15 |g month:12 |g pages:1518-1523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.25279 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2018 |e 12 |b 15 |c 12 |h 1518-1523 | ||